11/10/2025 – 08:30 AM
In a significant move to enhance its connected-care ecosystem, Tandem Diabetes Care, Inc. has announced the FDA clearance of the Tandem Mobi mobile app for Android devices.
Tandem Mobi Expands Accessibility
Based in San Diego, Tandem Diabetes Care (Nasdaq: TNDM) is recognized for its innovative insulin delivery solutions. The Tandem Mobi, touted as the world’s smallest and most durable automated insulin delivery system, is now set to reach a broader audience with the introduction of its Android-compatible mobile app.
The Tandem Mobi system, which operates on the advanced Control-IQ+ technology, has demonstrated impressive outcomes, including:
- Day 1 improvements
- 79% time in range
- 90% overnight time in range
John Sheridan, the company’s president and CEO, expressed enthusiasm about this development: “We’re excited to bring Tandem Mobi and the best-in-class outcomes of Control-IQ+ to Android users. This latest integration gives Android users access to the life-changing benefits of Control-IQ+ on a system that emphasizes convenience, discretion, and customization.”
The Tandem Mobi mobile app is designed to provide a secure and user-friendly experience, allowing users to manage their diabetes directly from their smartphones. With the addition of Android compatibility, the app enhances user engagement and facilitates better communication between patients and healthcare providers, ultimately leading to more informed treatment decisions.
Dr. Jordan Pinsker, the chief medical officer of Tandem, highlighted the app’s role in meeting patients where they are: “With the Tandem Mobi mobile app, we’re delivering a solution that meets patients on the devices they use every day, while maintaining the safety, reliability, and innovation they expect from Tandem.”
A limited release of the Tandem Mobi Android app is anticipated to commence in December 2025, with full commercial availability expected in early 2026. Once launched, users will be able to download the app from the Google Play Store on compatible devices, including Google Pixel models 6 through 10 and Samsung Galaxy models S21 through S25. A comprehensive compatibility list will be made available closer to the launch date.
For those interested in early access, Tandem invites potential users to sign up at this link.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care is dedicated to manufacturing and selling advanced automated insulin delivery systems that alleviate the challenges of diabetes management. Their product lineup includes the Tandem Mobi system and the t:slim X2 insulin pump, both featuring the innovative Control-IQ+ technology. The company continues to push the boundaries of diabetes care from its headquarters in San Diego, California. For more information, visit tandemdiabetes.com.
Follow Tandem Diabetes Care on social media platforms such as TikTok, Facebook, Instagram, LinkedIn, and X for the latest updates.
Important Safety Information: RX ONLY. The Tandem Mobi insulin pump and Control-IQ+ technology are intended for single patient use and should only be used as directed. For additional safety information, please visit tandemdiabetes.com/safetyinfo.
